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The critical role of intestinal microbiota in the success of allo-HSCT has been addressed in a few studies (reviewed in refs 2,3) mainly focusing on adult patients. We report here an in-depth profiling of the intestinal microbiota in five paediatric ALL patients treated with allo-HSCT. In our longitudinal study, we also followed the microbiota of six ALL patients receiving conventional induction therapy without HSCT, and compared microbiota recovery in the two patient groups.
Paediatric ALL patients at the Helsinki and Tampere University Hospitals were enrolled into the study. All patients entering HSCT received bone marrow grafts, in four cases from HLA-identical sibling donors ( Table 1 ). The sibling donors were also enrolled as controls for the microbiota of healthy children and adolescents. The study was approved by the Ethical Committee of the Helsinki University Hospital and the Review Board of Tampere University Hospital. A written informed consent was obtained from the participants' parents and from the participants 12 years of age or older.
We collected fecal samples from the HSCT patients once during or before conditioning and six times post HSCT (Table 1) . From the non-HSCT patients, the day-0 fecal sample was obtained at midconsolidation (a 9-week phase with peroral mercaptopurine and three high-dose methotrexate infusions 3 weeks apart), and thereafter 3-6 samples were collected (Table 1) . One fecal sample was collected from each sibling donor within 2-6 days before or after the bone marrow harvest. All samples were frozen at − 80°C within 24 h after defecation.
Total bacterial DNA was extracted from the samples as described. 4 The bar-coded pyrosequencing method was applied to microbiota profiling. The V4-V6 region of the 16S rRNA gene was PCR-amplified using a universal bacterial primer pair (F515 5′-TGYCAGCMGCCGCGGTA-3′; 1061 R 5′-TCACGRCACGAGCTGACG-3′). The PCR products were purified, pooled in equal amounts, and sequenced using a Genome sequencer FLX+ (Roche) in the Eurofins MWG (Germany). The trimming of sequences was performed in Mothur v.1.31.2. The sequencing provided 1.86 million reads, of which the 540 611 (29%) high-quality sequences were aligned and classified into bacterial taxa as described. 4 Microbiota diversity in the donors, determined as inverse Simpson diversity index (SDI), varied from 4.1 to 12.1 (mean SDI 8.2; Figure 1a ). This is comparable to previous data on healthy children's microbiota. 1, 5 In patient samples the diversity was markedly lower, with the mean SDI 1.7-5.8 in the HSCT group and 3.5-4.5 in the non-HSCT group, calculated from samples within comparable timeframes (Figure 1a) . No statistically significant differences in SDI were noted between the patient groups within any timeframe. The mean SDI in the patient samples increased gradually, but remained lower than in the healthy controls up to the end of the study period that lasted~6 months. The most striking difference to the healthy controls was seen in the HSCT group immediately (1-8 days) after transplantation (P o 0.05, Kruskall-Wallis test with Dunn's multiple comparisons).
The dominant microbial phyla in the donors were Firmicutes (44-84% of microbiota), Actinobacteria (4-47%) and Bacteroidetes (3-18%), while the proportion of Proteobacteria was low (0.1-0.3%) (Figure 1b) . In patient samples, the relative proportion of Proteobacteria was markedly higher, up to 6% in some samples from three patients in the non-HSCT group, and even 60% or over 90% in two samples from patient #3 in the HSCT group ( Figure 1b) .
The most dominant genera in the donors (representing over 10% of the microbiota in at least one donor) were Bifidobacterium, Bacteroides, Blautia and Faecalibacterium ( Figure 1c ). Altogether, 14-17 bacterial genera were observed within each healthy subject, with the most abundant genus comprising up to 40% of the microbiota. Enterococcus, Staphylococcus, Enterobacter, Bacteroides and unclassified genera of Lachnospriraceae were rare in donor samples, while they constituted over 90% of microbiota in the HSCT patient samples taken less than three weeks post-HSCT ( Figure 1c) . Conversely, the genus Feacalibacterium, which harbors the beneficial species F. prausnitzii, was undetectable in many patient samples. Most of the later post-HSCT samples began to resemble those of healthy children, with an increased relative abundance of members of normal intestinal microbiota, such as Blautia, Bifidobacterium and Roseburia (Figure 1c ).
Our results support previous studies that correlate immunosuppression, severe GvHD, and other HSCT complications with a decreased diversity of the intestinal microbiota and increased colonization with the genus Enterococcus and the phylum Proteobacteria. [6] [7] [8] [9] [10] Abundance of these microbial groups increases the risk for severe bloodstream infections, 6 emphasizing the importance of their detection. The early post-HSCT samples of patient #3, who had a severe, steroid-refractory grade IV GvHD, were dominated by Proteobacteria (Enterobacter and other, unclassified Enterobacteriacae) (Figures 1b and c) . The genus Enterococcus, in turn, dominated in at least one sample of all other HSCT patients (Figure 1c ). In the non-HSCT group, Enterococcus constituted nearly 70% of the microbiota in the day-1 sample of patient #6, and sporadical dominance of given microbial genera was noted also in some other samples, but less often than in the HSCT group (Figure 1c) .
In the patients #4 and #5, who had no signs of GvHD, the microbiota stabilized more rapidly than in the other HSCT patients (Figure 1c) . It was also of note that the pre-HSCT samples of patients #4 and #5 were rich in Bacteroidetes (Figure 1b) . A marked relative abundance of Bacteroidetes in the pre-HSCT samples of non-GvHD patients was also reported by Biagi et al. 0  20  34  75  124  173  8  16  34  44  71  100  161  231  34  49  85  121  208  33  53  81  188  1  46  68  138  193  63  176   0  0  0  0  0  20  34  75  124  173  8  16  34  44  71  100  161  231  34  49  85  121  208  33  53  81  188  1  46  68  138  193  63 increases with the growth of the child, 5 the noted trend towards a lower diversity in the immediate post-HSCT period is likely to reflect the toxic impact of the initial phase of HSCT on the intestine.
The main focus in our study was on the long-term characterization of individual variation in the microbiota composition and recovery after HSCT, with the follow-up time reaching 6 months (173-242 days). The only previous follow-up study completed with paediatric patients so far showed a temporal disruption of gut microbiota after HSCT in 10 patients and an emerging recovery towards the pre-HSCT microbial diversity during a follow-up period of 51-103 days. 8 Our results are in line with this, and the extended follow-up of our study provides evidence that in some patients, the recovery of diversity can take 5 months or even longer.
During HSCT, the intestinal ecosystem is predisposed to dysbiosis by various factors, including the post-HSCT phase of parenteral nutrition, and the often extensive antimicrobial medication. [11] [12] [13] Also chemotherapy as such renders the intestinal epithelium vulnerable to damage, and chemotherapy-induced neutropenia increases susceptibility to infections. All patients in our cohort were on trimethoprim/sulphamethoxazole prophylaxis and received broad-spectrum antibiotics for the treatment of bacterial infections. The HSCT patients received antifungal prophylaxis and treatment for suspected fungal infections during cytopenia. Four non-HSCT patients also received antifungal medication. The antibiotic exposures of each patient are detailed in Supplementary Figure S1 . As expected, the reduction in SDI often coincided with the administration of antimicrobials, but this was not the sole reason for the fluctuations in microbial diversity. A recent study described a reduced microbial diversity already at the diagnosis of paediatric ALL, with even more reduction among antibiotic-treated patients.
14 Thus, a complex set of factors ranging temporally from the pre-diagnosis period to maintenance seems to affect the microbiota of ALL patients.
In conclusion, our long-term follow-up study shows that the intestinal microbiota balance is markedly disturbed by allo-HSCT in the paediatric setting. Considerable reduction in microbial diversity and temporal variation in the phyla and genera were typical in fecal samples from HSCT patients. Reduced diversity was noted, to some extent, also among the non-HSCT patients, indicating that intensive ALL therapy in general disturbs the microbiota. However, HSCT seems to induce the most significant and enduring dysbiosis, warranting monitoring of intestinal microbiota during patient follow-up.
